WEKO3
アイテム
{"_buckets": {"deposit": "31e869a9-8ba9-4d58-8309-a1473efd3192"}, "_deposit": {"created_by": 1, "id": "86391", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "86391"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00086391", "sets": ["28"]}, "author_link": ["1054239", "1054232", "1054234", "1054235", "1054237", "1054242", "1054246", "1054244", "1054248", "1054238", "1054249", "1054236", "1054241", "1054245", "1054233", "1054247", "1054250", "1054240", "1054243"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2022-09-07", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background/Aims: Metabotropic glutamate receptor 1 (mGluR1), a key mediator of glutamatergic signaling, is frequently expressed as an oncoprotein and has been an attractive target to overcome most solid tumors, such as melanoma (1). Here, a novel small-molecular radiopharmaceutical pair, 3-iodo-N-[4-[6-(methylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-[11C]methylbenzamide ([11C]1) and 3-211At-astato-N-[4-[6-(methylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide ([211At]1), was designed and developed to target the mGluR1 for theranostics of melanomas. \nMethods: [ 11C]1 was synthesized by reacting a N-desmethyl precursor with [11C]CH3OTf in the presence of NaOH at room temperature for 5 min. Radiolabeling with [211At]1 was performed by reaction of aryl tin precursor with NCS-containing 211At/MeOH solution according to the method reported by our laboratory (2). The theranostic potentials of the radiopharmaceutical pair were explored for PET imaging and radiotherapy in mGluR1-positive B16F10 melanoma-bearing mice.\nResults: [ 11C]1 and [211At]1 were obtained with a radiochemical purity of greater than 99% and radiochemical yields of 19 ± 8 % and 46 ± 3%, respectively, based on the total radioactivity of used radionuclides. In vivo PET imaging of [ 11C]1 clearly visualized the targeted melanomas with a good tumor-to-background contrast. Ex vivo biodistribution study verified the persistent increase of [ 11C]1, which reached 12.29 ± 2.44 %ID/g tissue at 90 min in the targeted melanomas, and rapidly cleared from nontarget organs after intravenous injection. In the therapeutic studies, [211At]1 exhibited unequivocal and durable antitumor efficacy with only a single treatment (2.96 MBq) in the melanoma model, compared to the controls (0.31 ± 0.08 cm3 vs. 10.44 ± 1.61 cm3 at 16 days post-therapy). No decrease in body weight and no liver and kidney damage were observed through the examination period in melanoma mice injected with 2.96 MBq of [211At]1.\nConclusions: The novel small-molecular radiopharmaceutical pair successfully visualized the mGluR1-positive melanomas by [ 11C]1 with high contrast PET images, and further treated the melanoma by [211At]1 without significant toxicity. The results highlight the good potential of using [ 11C]1 and [211At]1 as theranostic agents for the management of mGluR1-positive tumors and should be further investigated in the theranostic field of oncology in the clinic.\n", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "第13回世界核医学会(13th orld Federation of Nuclear Medicine and Biology)", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Lin, Xie"}], "nameIdentifiers": [{"nameIdentifier": "1054232", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masayuki, Hanyu"}], "nameIdentifiers": [{"nameIdentifier": "1054233", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masayuki, Fujinaga"}], "nameIdentifiers": [{"nameIdentifier": "1054234", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Lulu"}], "nameIdentifiers": [{"nameIdentifier": "1054235", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Yiding"}], "nameIdentifiers": [{"nameIdentifier": "1054236", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wakana, Mori"}], "nameIdentifiers": [{"nameIdentifier": "1054237", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuan, Hu"}], "nameIdentifiers": [{"nameIdentifier": "1054238", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katsuyuki, Minegishi"}], "nameIdentifiers": [{"nameIdentifier": "1054239", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kotaro, Nagatsu"}], "nameIdentifiers": [{"nameIdentifier": "1054240", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong"}], "nameIdentifiers": [{"nameIdentifier": "1054241", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Lin, Xie", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054242", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masayuki, Hanyu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054243", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masayuki, Fujinaga", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054244", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Yiding", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054245", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wakana, Mori", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054246", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuan, Hu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054247", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katsuyuki, Minegishi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054248", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kotaro, Nagatsu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054249", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054250", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Development of metabotropic glutamate receptor 1-targeted radiopharmaceuticals for theranostics of melanoma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Development of metabotropic glutamate receptor 1-targeted radiopharmaceuticals for theranostics of melanoma"}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/86391", "pubdate": {"attribute_name": "公開日", "attribute_value": "2022-06-27"}, "publish_date": "2022-06-27", "publish_status": "0", "recid": "86391", "relation": {}, "relation_version_is_last": true, "title": ["Development of metabotropic glutamate receptor 1-targeted radiopharmaceuticals for theranostics of melanoma"], "weko_shared_id": -1}
Development of metabotropic glutamate receptor 1-targeted radiopharmaceuticals for theranostics of melanoma
https://repo.qst.go.jp/records/86391
https://repo.qst.go.jp/records/86391abca77bc-fd87-4d96-9ca7-a85d886aa266
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2022-06-27 | |||||
タイトル | ||||||
タイトル | Development of metabotropic glutamate receptor 1-targeted radiopharmaceuticals for theranostics of melanoma | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Lin, Xie
× Lin, Xie× Masayuki, Hanyu× Masayuki, Fujinaga× Zhang, Lulu× Zhang, Yiding× Wakana, Mori× Kuan, Hu× Katsuyuki, Minegishi× Kotaro, Nagatsu× Zhang, Ming-Rong× Lin, Xie× Masayuki, Hanyu× Masayuki, Fujinaga× Zhang, Yiding× Wakana, Mori× Kuan, Hu× Katsuyuki, Minegishi× Kotaro, Nagatsu× Zhang, Ming-Rong |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background/Aims: Metabotropic glutamate receptor 1 (mGluR1), a key mediator of glutamatergic signaling, is frequently expressed as an oncoprotein and has been an attractive target to overcome most solid tumors, such as melanoma (1). Here, a novel small-molecular radiopharmaceutical pair, 3-iodo-N-[4-[6-(methylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-[11C]methylbenzamide ([11C]1) and 3-211At-astato-N-[4-[6-(methylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide ([211At]1), was designed and developed to target the mGluR1 for theranostics of melanomas. Methods: [ 11C]1 was synthesized by reacting a N-desmethyl precursor with [11C]CH3OTf in the presence of NaOH at room temperature for 5 min. Radiolabeling with [211At]1 was performed by reaction of aryl tin precursor with NCS-containing 211At/MeOH solution according to the method reported by our laboratory (2). The theranostic potentials of the radiopharmaceutical pair were explored for PET imaging and radiotherapy in mGluR1-positive B16F10 melanoma-bearing mice. Results: [ 11C]1 and [211At]1 were obtained with a radiochemical purity of greater than 99% and radiochemical yields of 19 ± 8 % and 46 ± 3%, respectively, based on the total radioactivity of used radionuclides. In vivo PET imaging of [ 11C]1 clearly visualized the targeted melanomas with a good tumor-to-background contrast. Ex vivo biodistribution study verified the persistent increase of [ 11C]1, which reached 12.29 ± 2.44 %ID/g tissue at 90 min in the targeted melanomas, and rapidly cleared from nontarget organs after intravenous injection. In the therapeutic studies, [211At]1 exhibited unequivocal and durable antitumor efficacy with only a single treatment (2.96 MBq) in the melanoma model, compared to the controls (0.31 ± 0.08 cm3 vs. 10.44 ± 1.61 cm3 at 16 days post-therapy). No decrease in body weight and no liver and kidney damage were observed through the examination period in melanoma mice injected with 2.96 MBq of [211At]1. Conclusions: The novel small-molecular radiopharmaceutical pair successfully visualized the mGluR1-positive melanomas by [ 11C]1 with high contrast PET images, and further treated the melanoma by [211At]1 without significant toxicity. The results highlight the good potential of using [ 11C]1 and [211At]1 as theranostic agents for the management of mGluR1-positive tumors and should be further investigated in the theranostic field of oncology in the clinic. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 第13回世界核医学会(13th orld Federation of Nuclear Medicine and Biology) | |||||
発表年月日 | ||||||
日付 | 2022-09-07 | |||||
日付タイプ | Issued |